Recognition and screening for Chagas disease in the USA

Rachel Marcus; Andrés F. Henao-Martínez; Melissa Nolan; Elizabeth Livingston; Stephen A. Klotz; Robert H. Gilman; Monica Miranda-Schaeubinger; Sheba Meymandi

doi:10.1177/20499361211046086

Recognition and screening for Chagas disease in the USA

Rachel Marcus, Andrés F. Henao-Martínez, Melissa Nolan, Elizabeth Livingston, Stephen A. Klotz, Robert H. Gilman, Monica Miranda-Schaeubinger, Sheba Meymandi

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a public health concern, mainly among countries in South and Central America. However, despite the large number of immigrants from endemic countries living in the USA, awareness of CD is poor in the medical community, and therefore it is significantly underdiagnosed. To avoid the catastrophic cardiac complications of CD and to prevent maternal–fetal transmission, widespread educational programs highlighting the need for diagnosis are urgently needed.

Original language	English (US)
Journal	Therapeutic Advances in Infectious Disease
Volume	8
DOIs	https://doi.org/10.1177/20499361211046086
State	Published - 2021

Keywords

Chagas disease
Trypanosoma cruzi
USA
congenital Chagas
screening

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1177/20499361211046086

Cite this

@article{1a4fd0dbb794401986a13eb462ab43b8,

title = "Recognition and screening for Chagas disease in the USA",

abstract = "Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a public health concern, mainly among countries in South and Central America. However, despite the large number of immigrants from endemic countries living in the USA, awareness of CD is poor in the medical community, and therefore it is significantly underdiagnosed. To avoid the catastrophic cardiac complications of CD and to prevent maternal–fetal transmission, widespread educational programs highlighting the need for diagnosis are urgently needed.",

keywords = "Chagas disease, Trypanosoma cruzi, USA, congenital Chagas, screening",

author = "Rachel Marcus and Henao-Mart{\'i}nez, {Andr{\'e}s F.} and Melissa Nolan and Elizabeth Livingston and Klotz, {Stephen A.} and Gilman, {Robert H.} and Monica Miranda-Schaeubinger and Sheba Meymandi",

note = "Funding Information: The initial idea for the manuscript was raised at an advisory board organized by Bayer where CD was discussed. This publication and its content are solely the responsibility of the authors. Editorial assistance was provided by Simpson Healthcare, which was funded by Bayer. Simpson Healthcare is committed to adhering to the prevailing standards for {\textquoteleft}Good Publication Practice{\textquoteright} (GPP3), as well as the criteria for authorship established by the International Committee of Medical Journal Editors. Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

doi = "10.1177/20499361211046086",

language = "English (US)",

volume = "8",

journal = "Therapeutic Advances in Infectious Disease",

issn = "2049-9361",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Recognition and screening for Chagas disease in the USA

AU - Marcus, Rachel

AU - Henao-Martínez, Andrés F.

AU - Nolan, Melissa

AU - Livingston, Elizabeth

AU - Klotz, Stephen A.

AU - Gilman, Robert H.

AU - Miranda-Schaeubinger, Monica

AU - Meymandi, Sheba

N1 - Funding Information: The initial idea for the manuscript was raised at an advisory board organized by Bayer where CD was discussed. This publication and its content are solely the responsibility of the authors. Editorial assistance was provided by Simpson Healthcare, which was funded by Bayer. Simpson Healthcare is committed to adhering to the prevailing standards for ‘Good Publication Practice’ (GPP3), as well as the criteria for authorship established by the International Committee of Medical Journal Editors. Publisher Copyright: © The Author(s), 2021.

PY - 2021

Y1 - 2021

N2 - Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a public health concern, mainly among countries in South and Central America. However, despite the large number of immigrants from endemic countries living in the USA, awareness of CD is poor in the medical community, and therefore it is significantly underdiagnosed. To avoid the catastrophic cardiac complications of CD and to prevent maternal–fetal transmission, widespread educational programs highlighting the need for diagnosis are urgently needed.

AB - Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a public health concern, mainly among countries in South and Central America. However, despite the large number of immigrants from endemic countries living in the USA, awareness of CD is poor in the medical community, and therefore it is significantly underdiagnosed. To avoid the catastrophic cardiac complications of CD and to prevent maternal–fetal transmission, widespread educational programs highlighting the need for diagnosis are urgently needed.

KW - Chagas disease

KW - Trypanosoma cruzi

KW - USA

KW - congenital Chagas

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85115632207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115632207&partnerID=8YFLogxK

U2 - 10.1177/20499361211046086

DO - 10.1177/20499361211046086

M3 - Review article

AN - SCOPUS:85115632207

SN - 2049-9361

VL - 8

JO - Therapeutic Advances in Infectious Disease

JF - Therapeutic Advances in Infectious Disease

ER -

Recognition and screening for Chagas disease in the USA

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this